[Biomodulation of transcriptional factor NF-kappa B by ionizing radiation].
NF-kappaB (Nuclear Factor-kappaB) was described for the first time in 1986 as a nuclear protein binding to the kappa immunoglobulin-light chain enhancer. Since then, NF-kappaB has emerged as an ubiquitous factor involved in the regulation of numerous important processes as diverse as immune and inflammatory responses, apoptosis and cell proliferation. These last two properties explain the implication of NF-kappaB in the tumorigenic process as well as the promise of a targeted therapeutic intervention. This review focuses on the current knowledge on NF-kappaB regulation and discusses the therapeutic potential of targeting NF-kappaB in cancer in particular during radiotherapy.
Magné
N
N
Département de radiothérapie, institut Jules-Bordet, 121, boulevard de Waterloo, 1000 Bruxelles, Belgique. nicolas_magne@hotmail.com
Didelot
C
C
Toillon
R-A
RA
Van Houtte
P
P
Peyron
J-F
JF
D000975:Antioxidants / Q000502:physiology; D017209:Apoptosis / Q000502:physiology; D049109:Cell Proliferation; D002470:Cell Survival / Q000528:radiation effects; D006801:Humans; D007155:Immunologic Factors; D016328:NF-kappa B / Q000502:physiology* / Q000528:radiation effects*; D009369:Neoplasms / Q000209:etiology / Q000532:radiotherapy*; D010766:Phosphorylation; D061988:Proteasome Inhibitors; D011836:Radiation Tolerance; D011839:Radiation, Ionizing
D000975:Antioxidants; D007155:Immunologic Factors; D016328:NF-kappa B; D061988:Proteasome Inhibitors